Navigation Links
GenVec Expands Contract Supporting Malaria Vaccine Program
Date:7/27/2009

GAITHERSBURG, Md., July 27 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC) announced the expansion of an existing contract with the PATH Malaria Vaccine Initiative (MVI) to support the development of vaccines to fight malaria through MVI and USAID funding. This contract, valued at approximately $2 million, will continue a collaboration that began in 2004 and will initially support preclinical feasibility studies of novel adenovirus-based vaccines. Based on the results of the feasibility studies, GenVec, MVI, and USAID will contemplate preclinical and clinical development of these vaccines.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

"We appreciate the continued support from MVI and USAID and we look forward to advancing GenVec's vaccine technology through this collaboration," stated Dr. Joseph Bruder, head of GenVec's malaria program.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com'/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. ATS Medical Expands Open Pivot Heart Valve Offerings
3. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
4. BioLife Solutions Expands Scientific Advisory Board
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
7. Pharsight Expands Strategic Consulting Services Team
8. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
9. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
10. AQUISS Expands Into Significant New Territory
11. NanoBio Expands Drug Development Team for Its Anti-Infective Products

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)... , The concept of confinement is one of the ce...mple is that of quarks which bind together to form...elmholtz-Zentrum Berlin together with an internati...an experimental realization and a proof of confine...tem. , The concept of confinement states that in...
(Date:11/26/2009)...on of ultrasmall transistors and more powerful com...cting nanowires are closer to reality after a key ... and the University of California at Los Angeles. ...owires with layers of different materials that are...ritical requirement for making efficient transisto...
(Date:11/25/2009)...e/ - Cytochroma today announced the appointment of...oldt will replace Mr. Ulrik Spork as the Novo A/S ...of Board members remains unchanged at six members.... to the board and look forward to benefiting from ...s to make progress in becoming a leading CKD-focus...
(Date:11/24/2009)...e-FirstCall/ -- IES (Nasdaq: IESC ), a leading na...ystems and services for the commercial, industrial... commercial business group has been awarded a cont...rical systems for the Level 4 bio-safety lab (BSL-...esearch Institute of Infectious Diseases (USAMRIID...
Breaking Biology Technology:Spinons -- confined like quarks 2Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2
...ction July 27, 2008 Completes Enrollment for VEC... Md., Feb. 14 Vanda Pharmaceuticals,Inc. (Nasdaq:...he development,and commercialization of clinical-s... disorders, today announced financial and operatio... ended December 31, 2007., Vanda reported researc...
...nch; Positioned for Expanded Growth in ...th Quarter and 2007 Financial Highlights:, * Soli...illion in Q4 2007, compared to net product sale...s was $12.3 million, or $0.33 per share, compared ...er share, in Q3 2007., * Q4 non-GAAP net loss was...
...nced,today that the Chicago Athenaeum Museum of Ar...GN(TM) Award for the new SoloSTAR(R) disposable,in...e 2 diabetes., "LANTUS(R) SoloSTAR(R) and APIDRA(...intensive development, have been designed in dialo... high standards of the industry,",said Paul Jansen...
Other Biology Technology:Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 2Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 3Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 4Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 7Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 8Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 9Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 10Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 11Alexion Reports Fourth Quarter and Full Year 2007 Results 2Alexion Reports Fourth Quarter and Full Year 2007 Results 3Alexion Reports Fourth Quarter and Full Year 2007 Results 4Alexion Reports Fourth Quarter and Full Year 2007 Results 5Alexion Reports Fourth Quarter and Full Year 2007 Results 6Alexion Reports Fourth Quarter and Full Year 2007 Results 7Alexion Reports Fourth Quarter and Full Year 2007 Results 8Alexion Reports Fourth Quarter and Full Year 2007 Results 9Alexion Reports Fourth Quarter and Full Year 2007 Results 10Alexion Reports Fourth Quarter and Full Year 2007 Results 11Alexion Reports Fourth Quarter and Full Year 2007 Results 12Alexion Reports Fourth Quarter and Full Year 2007 Results 13Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 2Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 3Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 4Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 5
(Date:11/30/2009)...registration rates and register online now for the.../www.iofwco-ecceo10.org/ , WHAT: IOF WCO-ECCEO...orosis Foundation (IOF) and the European Society f...nd Osteoarthritis (ESCEO). More than 5,000 partici.... The exciting scientific programme includes 12 pl...
(Date:11/30/2009)...eeing your extended family over the holidays was s...n the December 2009 print issue of the Journal of...ows that you might be right. Here,s the good news:...y new treatments that help keep autoimmune disease... That,s because researchers from the University of...
(Date:11/30/2009)..., Nov. 30 Neurotechnology ( http:/...cision biometric identification technologies, has ...oduct line: VeriLook 4.0 Software Development Ki....1 SDK for large-scale multi-biometric and automat...nded capabilities in VeriLook 4.0 provide enhanced...
Breaking Biology News(10 mins):Seeing family for the holidays? Scientists discover how the stress might kill you 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Martin Hensen head of e strategies UCB Germany 3A Making e marketing more than just an add on 9458 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 2Five Questions About Protopic 28tacrolimus 29 Ointment 13332 3Five Questions About Protopic 28tacrolimus 29 Ointment 13332 4Synthetic biology opportunities and risks 53488 1Synthetic biology opportunities and risks 53488 2Synthetic biology opportunities and risks 53488 3
...lcome Fund has announced the recipients of the 200...Disease awards. , The Investigators in the Pathog...0 during a five-year period to encourage aggressiv...athogenesis. BWF launched the program in 2002 and... $30 million in the careers of investigators who a...
... has developed a new water treatment that could he.... , David Hand, a professor of civil and environm...simple way to treat ballast water in vessels rangi... designed to kill the virus that causes viral hemo...hat has been attacking fish populations in the low...
...the 2008 Environmental Scientists of the Year by T...rother, biologist Jules Blais, is the other winner...tigious in the environmental sciences. The prize r...ic work to Canadian society. , Smol is series ed...aleoenvironmental Research and has also edited man...
Other Biology News:BWF awards $7 million to infectious disease investigators 2New ballast treatment could protect Great Lakes fish 2
EZ-Retriever System from BioGenex
...00 drug discovery system miniaturizes, integrates ...ing LabChip technology, the LabChip 3000 performs ... fashion. LabChip assays are separations-based, so... in homogenous, well-based assays. No other screen...
Fluorogenic Chip, 4-Sipper from Caliper Life Sciences
...ystem, 100-120 and 220-240 V, is a microfluidics-b...ed electrophoresis, including some data analysis, ...or protein analysis (it does not include the vorte...ncludes the electrophoresis station, priming stati...
Biology Products: